(NASDAQ)
76.14
+0.22   (+0.29%)
After Hours: 76.80 +0.66 (+0.87%)
Volume (24h) Market Cap. Day Range 52w Range
4.31M 4.80B 76.04 - 83.95 14.01 - 99.95
Jan-15-21 05:45AM Editas Medicine (EDIT) Gains As Market Dips: What You Should KnowZacks
Jan-14-21 03:11AM With Rare Speed, Gene Editing Emerges as Biotech’s New Cutting EdgeBarrons.com
Jan-12-21 01:24AM Editas (EDIT) Gets FDA Nod to Begin Safety Study on EDIT-301Zacks
Jan-11-21 12:20PM Why Editas Medicine Stock Is Tumbling TodayMotley Fool
08:02AM The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex PharmaceuticalsZacks
Jan-11-21 06:05AM Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare ConferenceGlobeNewswire
06:02AM Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical TrialGlobeNewswire
Jan-11-21 06:00AM Editas Medicine Announces Transition of Chief Scientific OfficerGlobeNewswire
Jan-08-21 09:01AM CRISPR Gene Editing Stocks Up After Intellia's Pipeline UpdateZacks
Jan-07-21 04:24AM Genetics Stocks Pop After Intellia Offers Update For Gene-Editing DrugsInvestor's Business Daily
02:33AM Genetics Stocks Pop After Intellia Offers Update For Gene-Editing DrugsInvestor's Business Daily
Jan-07-21 08:42AM 3 Biotech Technological Developments to Watch Out For in 2021Zacks
Jan-06-21 11:00AM A New Gene-Editing Technique May Be Able to Help Children Who Prematurely AgeBarrons.com
Jan-05-21 06:23AM 3 Biotech Stocks That Could Double Your Money in 2021Motley Fool
Jan-04-21 04:05AM Editas Medicine to Present at the 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
09:27AM 5 Disruptive Biotech Stocks With Solid Long-Term PotentialZacks
Jan-04-21 06:09AM 3 Top Biotech Buyout Candidates in 2021Motley Fool
Dec-31-20 11:43AM What Type Of Shareholders Own The Most Number of Editas Medicine, Inc. (NASDAQ:EDIT) Shares?Simply Wall St.
Dec-29-20 12:27PM Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking TodayMotley Fool
Dec-24-20 11:10AM Top ETF of December & Its Best StocksZacks
Dec-23-20 07:29AM 12 Best Genomic Stocks to Buy NowInsider Monkey
01:30AM Stocks Showing Improved Relative Strength: Revance TherapeuticsInvestor's Business Daily
Dec-22-20 09:58AM Return On Capital Employed Overview: Editas MedicineBenzinga
Dec-21-20 04:24AM Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure DivesInvestor's Business Daily
12:43PM Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure DivesInvestor's Business Daily
Dec-21-20 12:12PM Why Editas Medicine Stock Is Skyrocketing TodayMotley Fool
Dec-17-20 04:05AM Editas Medicine Names Meeta Chatterjee, Ph.D., to Board of DirectorsGlobeNewswire
Dec-16-20 06:47AM Is EDIT A Good Stock To Buy Now?Insider Monkey
07:35AM 3 Growth Stocks for In-the-Know InvestorsMotley Fool
Dec-14-20 01:58AM Intra-Cellular Therapies Getting Closer To Key Technical BenchmarkInvestor's Business Daily
Dec-10-20 02:03AM CRISPR Gene Editing: Owning the Future of MedicineZacks
12:47PM Editas (EDIT) Submits Application to Start Study on EDIT-301Zacks
Dec-10-20 11:40AM Why Editas Medicine Stock Is Skyrocketing for the Fourth Day in a RowMotley Fool
09:44AM Looking Into Editas Medicine's Return On Capital EmployedBenzinga
Dec-10-20 07:42AM The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference PresentationsBenzinga
Dec-09-20 04:01AM Editas Medicine Announces Submission of IND Application for EDIT-301 with the FDAGlobeNewswire
11:27AM Why Editas Medicine Stock Is Rising for a Third Consecutive DayMotley Fool
Dec-09-20 11:06AM Gene-Editing Stocks Skyrocket in $1.6 Billion Boom After DataBloomberg
Dec-08-20 03:41AM Why Editas Medicine Stock Jumped Again TodayMotley Fool
Dec-07-20 11:41AM Why Editas Medicine Stock Is Soaring TodayMotley Fool
Dec-05-20 11:32AM Editas (EDIT) Up 9.3% Since Last Earnings Report: Can It Continue?Zacks
10:00AM Editas Medicine Announces Preclinical Data and Large-Scale Manufacturing Process for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-ThalassemiaGlobeNewswire
Nov-10-20 04:01AM Editas Medicine Reports Inducement Grants to New Chief Medical OfficerGlobeNewswire
05:41AM Editas Medicine, Inc. (NASDAQ:EDIT) Analysts Just Slashed Next Year's Revenue Estimates By 20%Simply Wall St.
Nov-09-20 04:05AM Editas Medicine to Present at Barclays Gene Editing & Gene Therapy SummitGlobeNewswire
09:00AM Editas Medicine Appoints Lisa A. Michaels, M.D., as Chief Medical OfficerGlobeNewswire
Nov-07-20 09:06AM Editas Medicine, Inc. Beat Analyst Profit Forecasts, And Analysts Have New EstimatesSimply Wall St.
Nov-06-20 03:30AM Editas Medicine, Inc. (EDIT) Q3 2020 Earnings Call TranscriptMotley Fool
11:24AM Editas' (EDIT) Earnings Rise Y/Y in Q3, EDIT-101 in FocusZacks
Nov-05-20 05:25AM Editas Medicine (EDIT) Tops Q3 Earnings and Revenue EstimatesZacks
Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Cap:    |  Volume (24h):